PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Data show drug being tested to reduce cardiovascular events increased risk of heart attack

VISTA-16 trial was halted for futility and possible harm in 2012

2013-11-19
(Press-News.org) Contact information: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Data show drug being tested to reduce cardiovascular events increased risk of heart attack VISTA-16 trial was halted for futility and possible harm in 2012 Monday, Nov. 18, 2013, Cleveland: Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events – including sudden death, heart attack and stroke – than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

The results of the VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) trial, which was halted last year for futility and possible harm, were presented today at the American Heart Association Scientific Sessions 2013 in Dallas and published simultaneously in the Journal of the American Medical Association (JAMA).

Varespladib inhibits production of the compound secretory phospholipase A2 (sPLA2), which promotes the vascular inflammation implicated in the development of atherosclerosis, or the clogging and hardening of arteries.VISTA-16 was designed to test whether the use of varespladib to reduce sPLA2 would lower the risk of cardiovascular events in patients with acute coronary syndrome. Patients with acute coronary syndrome have had a heart attack or experienced unstable angina, which can lead to a heart attack.

Rather than reduce additional cardiovascular events, including sudden death, heart attack, stroke, and unstable angina, the study found that patients treated with varespladib were more likely than those treated with placebo to experience these events. Both groups of patients were also treated with statin therapy and standard-of-care protocols. The primary endpoint, a composite of sudden death, heart attack, stroke and unstable angina, occurred in 6.1 percent of patients on varespladib compared to 5.1 percent of those on placebo.

In addition, the study found that varespladib was associated with a significantly greater risk of heart attack, occurring in 3.4 percent of the study population on varespladib and 2.2 percent of those on placebo.

After reviewing this data, the trial's independent Data and Safety Monitoring Board called off the trial in March 2012.

"Despite prior experimental and observational data suggesting that varespladib would have beneficial cardiovascular effects, this trial proves the contrary, that it is actually detrimental to cardiovascular morbidity and mortality," said VISTA-16 executive committee chair Stephen J. Nicholls, M.D., Ph.D., senior consultant to Cleveland Clinic's C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia.

"The drug cannot be used to prevent cardiovascular events in patients with acute coronary syndrome," he said.

The researchers do not know whether the outcome of the VISTA-16 trial is attributable to the varespladib molecule itself, or the across-the-board inhibition of sPLA2, which is known to have both protective and inflammatory affects on the cardiovascular system.

"We know that vascular inflammation plays a significant role in the development of coronary disease, and it's important for the scientific community to continue to pursue drugs that may ease the inflammatory process and reduce cardiovascular risk," said Steven Nissen, M.D., senior author on the JAMA paper and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. "Unfortunately, the complexity of the inflammatory process continues to confound our efforts at taming it."

VISTA-16 was a double-blind, randomized, placebo-controlled trial designed to enroll more than 5,000 patients at 362 academic and community hospitals in Australia, Europe, India, New Zealand, and North America. It was an academically directed trial developed by an independent executive steering committee with input from the sponsor, Anthera Pharmaceuticals, and monitored by a Data and Safety Monitoring Board independent from both the executive committee and the sponsor.

INFORMATION:

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, currently under construction, Cleveland Clinic Abu Dhabi. In 2012, there were 5.1 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at http://www.clevelandclinic.org. Follow us at http://www.twitter.com/ClevelandClinic.



ELSE PRESS RELEASES FROM THIS DATE:

Adult survivors of childhood cancer at risk of becoming frail at an early age

2013-11-19
Adult survivors of childhood cancer at risk of becoming frail at an early age St. Jude Children's Research Hospital study finds that young adults who had cancer as children are more likely to be frail than their peers; this condition leaves survivors ...

Chaotic physics in ferroelectrics hints at brain-like computing

2013-11-19
Chaotic physics in ferroelectrics hints at brain-like computing OAK RIDGE, Tenn., Nov. 18, 2013—Unexpected behavior in ferroelectric materials explored by researchers at the Department of Energy's Oak Ridge National Laboratory supports a new approach ...

Biologists find an evolutionary Facebook for monkeys and apes

2013-11-19
Biologists find an evolutionary Facebook for monkeys and apes Why do the faces of some primates contain so many different colors — black, blue, red, orange and white — that are mixed in all kinds of combinations and often striking patterns ...

In pandemic, parents who get reminders more likely to get kids vaccinated

2013-11-19
In pandemic, parents who get reminders more likely to get kids vaccinated U-M researchers find state's immunization registry can be used to spur parents of children with chronic illness to get vaccinated during pandemic Ann Arbor, Mich. — A new University ...

Are prisoners with military mettle more likely to toe the line or cross it?

2013-11-19
Are prisoners with military mettle more likely to toe the line or cross it? University of Cincinnati research examines whether prison inmates with military backgrounds are more likely to misbehave The military lifestyle can be one of extremes: the orderliness ...

New program offers blueprint and 'Golden Rules' for increasing sustainable electricity in developing country governments

2013-11-19
PUBLIC RELEASE DATE: 19-Nov-2013 [ | E-mail ] var addthis_pub="eurekalert"; var addthis_options = "favorites, delicious, digg, facebook, twitter, google, newsvine, reddit, slashdot, stumbleupon, buzz, more" Share Contact: Terry Collins tc@tca.tc 416-538-8712 Adriana Paez paez.adriana@hydro.qc.ca 514-392-5642 Global Sustainable Electricity Partnership New program offers blueprint and 'Golden Rules' for increasing sustainable electricity in developing country governments Global outreach effort by electricity giants fosters bottom-up approach to ...

Study finds altered brain connections in epilepsy patients

2013-11-19
Study finds altered brain connections in epilepsy patients OAK BROOK, Ill. – Patients with the most common form of focal epilepsy have widespread, abnormal connections in their brains that could provide clues toward diagnosis and treatment, according ...

Age affects short-term quality of life after breast biopsy

2013-11-19
Age affects short-term quality of life after breast biopsy OAK BROOK, Ill. – Breast biopsies can adversely affect short-term quality-of-life, and the effects are more pronounced in younger patients, according to a new study published online in the journal ...

New method to diagnose sepsis is faster, cheaper

2013-11-19
New method to diagnose sepsis is faster, cheaper WASHINGTON, DC – November 15, 2013 – A new method could cut hours off the time it takes to diagnose blood infections while also eliminating the need for complicated manual processing and expensive equipment, according ...

Liberals aren't like the rest, or so they think

2013-11-19
Liberals aren't like the rest, or so they think Liberals tend to underestimate the amount of actual agreement among those who share their ideology, while conservatives tend to overestimate intra-group agreement, according to new research ...

LAST 30 PRESS RELEASES:

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

Antibiotic resistance among key bacterial species plateaus over time

‘Some insects are declining but what’s happening to the other 99%?’

Powerful new software platform could reshape biomedical research by making data analysis more accessible

Revealing capillaries and cells in living organs with ultrasound

American College of Physicians awards $260,000 in grants to address equity challenges in obesity care

Researchers from MARE ULisboa discover that the European catfish, an invasive species in Portugal, has a prolonged breeding season, enhancing its invasive potential

Rakesh K. Jain, PhD, FAACR, honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research

Solar cells made of moon dust could power future space exploration

Deporting immigrants may further shrink the health care workforce

Border region emergency medical services in migrant emergency care

Resident physician intentions regarding unionization

Healthy nutrition and physical lifestyle choices lower cancer mortality risk for survivors, new ACS study finds

[Press-News.org] Data show drug being tested to reduce cardiovascular events increased risk of heart attack
VISTA-16 trial was halted for futility and possible harm in 2012